Absci (ABSI) and Owkin said Friday that they formed a partnership to develop therapeutic candidates addressing novel targets in immuno-oncology and other indications such as inflammation.
The partnership will use Owkin's predictive AI models to optimize target selection and validate therapeutic hypotheses, while Absci's generative AI Drug Creation platform will design therapeutic candidates against the selected novel targets, according to a joint statement.
Financial terms were not disclosed.
Shares of Absci were down more than 9% in recent trading.
Price: 2.92, Change: -0.30, Percent Change: -9.32
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.